Group items tagged

One evening whilst I was watching TV, my phone pinged with an all too familiar WhatsApp alert with a message preview saying "Can you help". I recognised the name as one of our Titan pharmacy customers who was clearly in a state of panic. I replied offering my assistance and asked him what was up. What followed over the next 24 hours was an interesting case study of how innovative technology can genuinely solve real challenges in pharmacies. Mr P (let's call him that) had booked a locum to cover in his dispensary on the next day so he could focus on his vaccination service. The problem - his locum had just called to cancel his booking (no reason given) and now he had no cover. Meanwhile, he was fully booked with back to back appointments and could not cancel them. He had phoned round his usual network of pharmacists and no one was available at short notice. He was asking if there was anything that Titan could do to reduce his workload and said he had heard about Titan's artificial intelligence module. Unfortunately, Titan. X had not been installed at this site and was not an option at this late stage. Equally, Titan's digital workflow cannot be circumvented so there was no way steps could be taken out of the process.

Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up recruitment in studies conducted by drugmakers. With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and access to an extensive foundation of pharmacy and patient-authorised clinical data. The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants, the company will be able to reduce the time it takes to match eligible patients to clinical trials. "Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer, Walgreens.

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS. Lipoedema is more prevalent in women and very rarely affects men. It is characterised by an abnormal, usually symmetrical, accumulation of fat in the legs, hips, buttocks, and occasionally arms. It is a separate condition to obesity and lymphoedema. The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health. The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that several different liposuction techniques are used and that they may have different safety and efficacy profiles.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

Endocrinology is the study of hormones and glands in the human body. The endocrine system produces and secretes hormones that regulate many bodily functions, including growth and development, metabolism, and reproductive health. Endocrinologists are physicians who specialize in diagnosing and treating hormonal imbalances and disorders. There are several reasons why you might consider seeing an endocrinologist. In this article, we'll explore some of the most common reasons people seek out the expertise of an endocrinologist. YOU HAVE DIABETES If you have diabetes, it is important to consider seeing an endocrinologist. Endocrinologists specialize in managing diabetes and can help you develop a personalized treatment plan to manage your blood sugar levels. They can also help you prevent or manage complications of diabetes, such as nerve damage, kidney disease, and eye problems. An endocrinologist can work with you to develop a healthy lifestyle plan that includes diet, exercise, and medication management. They can also help you adjust your treatment plan as needed to ensure that your diabetes is well-controlled. Seeing an endocrinologist can help you achieve better health outcomes and improve your overall quality of life.

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

Community pharmacy could play an important role in proactive detection of heart valve disease (HVD), which remains under-recognised and under-detected in England, suggested a new report published by Wilmington Healthcare. Pharmacy bodies, including Royal Pharmaceutical Society (RPS), National Pharmacy Association (NPA) and Community Pharmacy England (CPE), have also endorsed the report, which encourages Integrated Care Boards (ICBs) to consider the innovative approach of detecting HVD with the help of community pharmacists. Despite HVD detection being a priority listed in the NHS Long Term Plan, a large number of people with HVD remained undiagnosed and untreated in the country due to lack of awareness of the disease prevalence. In June 2022, a pilot study was launched in Farnborough Primary Care Network (PCN), Hampshire, to evaluate the feasibility of using e-stethoscopes (digital auscultation) to detect this heart condition by a community pharmacist.

The UK based Pharma giant Futura Medical Plc's lead product, Eroxon, a topical Stim-gel is now available on NHS prescription in England and Wales for the treatment of Erectile Dysfunction (ED). The Muti-Drug Resistant (MDR) approved alternative to PDE5i, Eroxon is available as an over-the counter off shelf at retailers like Boots and Superdrug; and is available on NHS prescription in England and Wales as a CE-marked medical device. Erectile dysfunction (ED), also known as impotence, is the inability to get and maintain an erection, typically concerning men over the age of 40 due to both, psychological and physical causes such as anxiety, depression, diabetes, and obesity. According to UK Conformity Assessed (UKCA), the approval of the medication is based on evidence from 2 Phase three clinical studies, which showed that 60 per cent of patients taking Eroxon achieved Minimal Clinically Important Differences (MCID) at 12 weeks.

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage. Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest CT scan, if appropriate. Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website. The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and 61 per cent in women.

A recent study, conducted by CBD experts at Brown's CBD, unveiled Dundee as the UK's leading CBD hotspot, with an average monthly search volume of 530.29 per 100,000 residents, sparking a surge of interest in natural wellness solutions. New research analysed search volume data across UK cities for CBD-related terms, reflecting a staggering 1100% increase in searches for 'what is CBD' over the last decade. Following Dundee, Brighton secures the second spot in the rankings with an average monthly search volume of 530.08 per 100,000 residents for CBD related terms, closely trailed by St. Albans in third place. Other notable cities making the top ranks include Gloucester, Hereford, and Bath, indicating a widespread curiosity about CBD products and their purported health benefits.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Monday (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat invasive candidiasis, an infection caused by a yeast called Candida. Invasive candidiasis can pose a serious health risk as it can affect the blood, heart, brain, eyes, bones and other parts of the body. Napp Pharmaceuticals Ltd was granted the marketing authorisation for the medicine based on phase 3 clinical trial data. In the randomised, double-blind, controlled study, more than half of the invasive candidiasis patients who were given a weekly dose of rezafungin were cured at day 14. Among 94 patients who were given a daily dose of caspofungin (another antifungal treatment), 57 of them were cured during the same time.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

In 2023, almost 14,000 people in England are estimated to have died due to excessive waits in emergency departments, averaging more than 260 deaths per week, according to new figures from the Royal College of Emergency Medicine (RCEM). The RCEM estimate is based on a large study of NHS patients published in the Emergency Medicine Journal in 2021, which found one excess death for every 72 patients who spent eight to 12 hours in an A&E department. Following a Freedom of Information audit of NHS trusts, the college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed. NHS data for England revealed that over 1.5 million patients waited 12 hours or more in major emergency departments last year. Based on the RCEM calculation, this indicates that over a million of those patients were waiting for a bed.

The incredible consequences that drug misuse has imposed on humans in the last few years make it one of the most pressing issues facing such nations. A person who is addicted to drugs or alcohol often turns to these substances as a crutch while they're going through tough times. Taking the drug regularly becomes habitual since it provides short-term relief without permanently resolving the issue. An important part of becoming sober is learning to substitute better routines for the addict's old, harmful ones. These self-care routines and healthy habits are much better ways to deal with stress. Here we will explain how healthy behavior throughout addiction recovery is simply one of many methods to adapt to life after treatment. Physical Activity Scientific studies have shown that physical activity increases levels of two hormones. dopamine and serotonin, which are linked to better mood. A more positive outlook, restful sleep, and enhanced general health are all possible outcomes of these hormones. In the early stages of your rehabilitation, it is wise to start an exercise regimen that you have never done before. You may find new sober friends and interactions, as well as inspiration to improve your physical health, by connecting with other people who share your interests in physical activity. In the early stages of recovery, having sober friends may be really helpful since it allows you to connect with those who understand what you're going through. Friendships formed in early recovery often continue long after the addict has left the program, according to many people in recovery.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

The Food Standards Agency (FSA) has launched a campaign to caution people with food allergies about the risk of products labelled as 'vegan'. People who have an allergy to milk, eggs, fish and crustaceans or molluscs are encouraged to always check for a precautionary allergen statement such as 'may contain' on products labelled 'vegan' before consuming the food. The launch of the campaign comes in the wake of recent research findings by the FSA that 62 per cent of individuals with reactions to animal-based products or who buy for someone with allergies were confident that products labelled 'vegan' are safe to eat. This is "incorrect" and may put them at risk, the agency said. The FSA study found that 54 per cent of people who experience reactions to animal-based products and 53 per cent of those purchasing for someone with a food hypersensitivity to animal-origin products have used vegan labelling to determine the safety of packaged food on at least some occasions.